12

2023

-

01

Hubei Guangchen Pharmaceutical Allopurinol API Transfer A

Author:

On January 12, 2023, our company transferred allopurinol API to A, and the packaging specifications of this product are: 1kg/barrel, 5kg/barrel, 10kg/barrel, 25kg/barrel, or can be provided according to customer requirements.

On January 12, 2023, our company transferred allopurinol API to A, and the packaging specifications of this product are: 1kg/barrel, 5kg/barrel, 10kg/barrel, 25kg/barrel, or can be provided according to customer requirements.

1

Allopurinol and its metabolites can inhibit xanthine oxidase, prevent hypoxanthine and xanthine from converting to uric acid, thereby reducing the concentration of uric acid in the blood, reducing the deposition of uric acid salts in bones, joints, and kidneys, and can inhibit the production of uric acid synthesis.

Related News

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Linagliptin-Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Linagliptin/metformin extended-release tablets (I), marketed under the brand name LedaTang®, is a combination antidiabetic formulation manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. and held as the marketing authorization holder; it is also the first extended-release formulation of its kind approved for marketing in China.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tang — a pharmaceutical product for the treatment of diabetes, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

LE DA TANG is a pharmaceutical brand dedicated to the treatment of diabetes, with its flagship product being “LE DA TANG® Linagliptin–Metformin Extended-Release Tablets (I).” This combination antidiabetic formulation contains the DPP‑4 inhibitor linagliptin and the biguanide metformin hydrochloride. Manufactured by Hubei Guangchen Pharmaceutical Co., Ltd., it is the first domestically approved extended-release formulation of its kind, indicated for glycemic control in adult patients with type 2 diabetes who are suitable for treatment with both linagliptin and metformin.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

Leda Tanglirgeletin Metformin Extended-Release Tablets (I) — a combination antidiabetic formulation under the Leda Tang brand, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd.

2026-10-19

Ledar Tang® Linagliptin-Metformin Extended-Release Tablets (I) are the first domestically approved extended-release formulation, manufactured by Hubei Guangchen Pharmaceutical Co., Ltd. This product combines the DPP‑4 inhibitor linagliptin with metformin hydrochloride; it is taken once daily, one tablet per dose, with meals, and is indicated, in conjunction with dietary management and exercise, for glycemic control in adult patients with type 2 diabetes who are suitable candidates for treatment with both linagliptin and metformin.

Hubei Guangchen Pharmaceutical Co., Ltd. Has Been Recognized as a Credible Enterprise Abiding by Contracts for the 15th Yichang Session (2024–2025)

2026-08-03